What are top 5 catalysts for psychedelic stocks in the second half of 2021? Stay tuned to hear how stocks like MindMed (NASDAQ: MNMD),
(NEO:MMED), Compass Pathways (NASDAQ: CMPS), atai Life Sciences ( NASDAQ: ATAI), Tryp Therapeutics, Cybin and more will affect the psychedelic industry in 2021.
0:00 – Intro
1:38 – #5: A New Psychedelics ETF (PSIL)
4:57 – #4:California Decriminalizing possession of psychedelics, and Legalising the personal production of Psilocybin
7:30 – #3:The commencement of MANY phase 2a trials
10:16 – #2: MindMed’s Project Lucy phase 2b trial begins
11:47 – #1: Compass Pathways phase 2b trial results released
Enjoy the episode!
Follow us on social media! 🙌
Want to collaborate? Send us an email at:
Check out our website: thepsychedelicinvestor.com
Check out our Benziga discounts
#MindMed #MNMD #PsychedelicStocks
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.